Risk Flags
elevated_costElevated long-acting opioid rate
Risk indicators are statistical patterns, not allegations. Learn more
1,460
Total Claims
$5.4M
Drug Cost
242
Beneficiaries
$22K
Cost/Patient
Risk Score Breakdown 7/100
Low (0)Moderate (15)Elevated (30)High (50+)
Long-acting opioid rate+4
Cost per patient outlier+3
Score components are additive. Read full methodology
Peer Comparison vs. 8,541 Hematology-Oncology providers
+157%
Opioid rate vs peers
16.1% vs 6.3% avg
+65%
Cost per patient vs peers
$22K vs $14K avg
+91%
Brand preference vs peers
27.9% vs 14.6% avg
Opioid Prescribing
16.1%
Opioid Rate
235
Opioid Claims
$12K
Opioid Cost
42.1%
Long-Acting Rate
Brand vs Generic
72% generic
Brand: 407 claims · $5.3M
Generic: 1,053 claims · $160K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Palbociclib | 71 | $1.1M |
| Lenalidomide | 28 | $509K |
| Cabozantinib S-Malate | 17 | $424K |
| Ibrutinib | 27 | $423K |
| Venetoclax | 27 | $422K |
| Abemaciclib | 19 | $311K |
| Enzalutamide | 21 | $252K |
| Olaparib | 13 | $250K |
| Nilotinib Hcl | 12 | $242K |
| Dasatinib | 12 | $220K |
| Abiraterone Acetate | 38 | $121K |
| Apixaban | 32 | $39K |
| Lipase/Protease/Amylase | 19 | $35K |
| Morphine Sulfate | 82 | $2,503 |
| Letrozole | 82 | $2,007 |
Prescribing Profile
Patient Profile
73
Avg Age
65%
Female
2.24
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About